Azenta (NASDAQ:AZT) shares fell Wednesday after the company reported first-quarter earnings that missed analyst estimates, as costs related to its ongoing business turnaround pressured profit margins.
Boston Scientific (NYSE:BSX) reported fourth-quarter results that topped analyst estimates, driven by a double-digit surge in its cardiovascular division and a string of regulatory wins that are reshaping its competitive landscape.
GE HealthCare Technologies (NASDAQ:GEHC) delivered a strong finish to 2025, reporting fourth-quarter sales that outpaced expectations and providing a 2026 forecast that signals continued margin expansion for the medical-tech giant.
MiNK Therapeutics (NASDAQ:INKT) unveiled new translational data at the Keystone Symposia on Wednesday, providing the first direct evidence in humans that a specific immune cell deficiency may be a primary driver of the scarring that defines idiopathic pulmonary fibrosis (IPF).
GSK (NYSE:GSK) reported fourth-quarter results that cleared Wall Street estimates, as the British drugmaker successfully leveraged its high-growth specialty medicines to offset slowing demand for its flagship RSV vaccine, Arexvy.
Novartis (NYSE:NVS) reported fourth-quarter adjusted earnings that beat analyst estimates on Wednesday, but the Swiss pharmaceutical giant issued a cautious 2026 outlook as it prepares to navigate the largest wave of patent expirations in its history.
Novo Nordisk (NYSE:NVO) reported fourth-quarter results on Wednesday that exceeded analyst expectations, but shares plummeted as the Danish pharmaceutical giant issued a "shocking" outlook for 2026, warning of a potential double-digit decline in sales and profit.
Mesa Laboratories (NASDAQ:MLAB) reported a sharp increase in profitability for its third fiscal quarter, as strong demand for its biopharmaceutical tools more than offset a collapse in its Chinese diagnostic business.
National Research Corporation (NASDAQ:NRC), the experience-improvement firm known as NRC Health, reported fourth-quarter results that signaled a steady operational turnaround, bolstered by a fifth consecutive quarter of growth in its core recurring contract base.
Pfizer (NYSE:PFE) announced positive topline results from the Phase 2b VESPER-3 study evaluating monthly maintenance dosing of its fully-biased, ultra-long-acting injectable GLP-1 receptor agonist PF’3944 (nexiguran ziclumeran) in adults with obesity or overweight without type 2 diabetes.
Pfizer (NYSE:PFE) reported fourth-quarter and full-year 2025 results on Tuesday, February 3, 2026, signaling a definitive shift away from its pandemic-era reliance.
Merck (NYSE:MRK) today reported fourth-quarter and full-year 2025 results that showcased a tale of two portfolios: a surging oncology and respiratory business set against a dramatic collapse in vaccine demand from China.
